Oncolytics Biotech (ONCY) Other Non Operating Income (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Other Non Operating Income of $101728.9 for Q3 2025, up 213.75% year-over-year from $32423.6 in Q3 2024, and up 149.98% quarter-over-quarter from -$203522.9 in Q2 2025.
Oncolytics Biotech (ONCY) Other Non Operating Income (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Other Non Operating Income for 13 consecutive years, with $101728.9 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Non Operating Income rose 213.75% year-over-year to $101728.9; the TTM figure through Sep 2025 stood at $136117.6 (down 3.35% YoY), while the FY2025 annual figure was $45000.0, down 98.42% from the prior year.
- Other Non Operating Income rose to $101728.9 in Q3 2025 per ONCY's latest filing, from -$203522.9 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.2 million in Q3 2022 and bottomed at -$513622.0 in Q2 2021.
- Historically, Other Non Operating Income has averaged $73013.2 across 5 years, with a median of -$35542.7 in 2025.
- Annual changes were most pronounced in 2024 — Other Non Operating Income surged 51768.92% — and 2025, when it plunged 251.28%.
- Oncolytics Biotech's Other Non Operating Income stood at -$258757.7 in 2021, then rose by 21.99% to -$201856.6 in 2022, then tumbled by 42.64% to -$287937.9 in 2023, then jumped by 194.97% to $273454.4 in 2024, then slumped by 62.8% to $101728.9 in 2025.
- Business Quant data shows ONCY's Other Non Operating Income at $101728.9 in Q3 2025, -$203522.9 in Q2 2025, and -$35542.7 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38,000.00 |
| Sep 30, 2025 | 101,728.90 |
| Jun 30, 2025 | -203,522.92 |
| Mar 31, 2025 | -35,542.74 |
| Dec 31, 2024 | 273,454.37 |
| Sep 30, 2024 | -89,432.52 |
| Jun 30, 2024 | 134,529.86 |
| Mar 31, 2024 | 383,672.53 |
| Dec 31, 2023 | -287,937.93 |
| Sep 30, 2023 | 231,238.45 |
| Jun 30, 2023 | -293,314.27 |
| Mar 31, 2023 | 739.70 |
| Dec 31, 2022 | -201,856.61 |
| Sep 30, 2022 | 1.17 Mn |
| Jun 30, 2022 | 696,494.50 |
| Mar 31, 2022 | -374,211.34 |
| Dec 31, 2021 | -258,757.67 |
| Sep 30, 2021 | 962,879.69 |
| Jun 30, 2021 | -513,622.00 |
| Mar 31, 2021 | -308,576.37 |